Researchers studying ketamine as suicide prevention drug

by Bob Shepard

(Medical Xpress)—University of Alabama at Birmingham (UAB) researchers think ketamine, an anesthesia medication in use since the 1970s, might be a valuable tool in treating severe depression and reducing suicidal urges; they have launched two studies to explore the possibility. One of the studies, ketamine is administered to suicidal patients in the UAB Hospital emergency department (ED), is the only such trial actually being conducted in an ED in the nation.

"There is a growing body of evidence that indicates that lower doses of ketamine can reduce suicidal feelings and relieve symptoms of in a very short period of time, as little as a few hours, which makes it an extremely attractive candidate for treating acute depression," said Richard Shelton, M.D., professor in the Department of Psychiatry and Behavioral Neurobiology and lead investigator on the studies.

Shelton said ketamine appears to work on depression by blocking a neurotransmitter called glutamate from binding to the on neurons. Too much glutamate on an NMDA receptor leads to the opening of a channel, releasing too much calcium downstream. This then affects a , (BDNF), which increases connections between neurons in the brain. These connections help the brain regulate emotions better.

In the trial, patients presenting to the ED with suicidal thoughts can be enrolled in the ketamine trial. The drug is administered via infusion, which takes about five minutes.

"We have seen a decrease in depression scores and suicide scores, sometimes within 15 minutes after giving ketamine," said Cheryl McCullumsmith, M.D., Ph.D., assistant professor and director of hospital psychiatry. "The antidepressants commonly used to treat depression and suicidal thoughts take weeks or months to begin to show positive effects. When a patient is actively suicidal, we don't have that much time."

McCullumsmith said patients entered in the ketamine trial at the ED are admitted to the psychiatric inpatient unit for observation.

"We are attempting to determine just how quickly the drug produces a beneficial result, as well as how long that result lasts," McCullumsmith said.

Shelton said a second trial, sponsored by Janssen Research & Development, LLC., is a multi-site trial of patients with severe depression and possible who are seen in an outpatient setting. Patients receive two or three infusions of ketamine or placebo each week for four-to-six weeks. Patients who do not benefit from study treatment after the first two weeks are offered two weeks of treatment with ketamine without the chance of placebo.

"We're interested in knowing how long each infusion will sustain the beneficial effect," said Shelton. "Ketamine does not appear to be curative, and we have a lot of work to do to see if it might be a useful drug for depression and suicide prevention on a long-term, regular-use basis."

A third trial underway at UAB is testing a compound called Glyx-13, produced by Naurex, Inc. Glyx-13 may produce similar results as ketamine by blocking an amino acid called glycine, which works in tandem with glutamate. Glycine regulates glutamate signaling, so it is like an added layer of fine-tuning. When glycine and glutamate bind to NMDA together, the calcium opens widely. Blocking glutamate with ketamine can reduce the release of calcium. Blocking glycine with Glyx-13 may achieve the same result, but more subtly and with fewer side effects.

"Glyx-13 may prove to be a more promising candidate than ketamine in terms of potential side effects," said Shelton. "Glyx-13 is being evaluated with just one infusion per week."

Ketamine, when used in anesthesia, has some side effects, including hallucinations and psychotic symptoms. It has also been a drug of abuse, known on the street as Special K. Shelton said the dose used in the trials is much lower, and given over a longer period. observed thus far in the ketamine trials have been minimal, he said.

More information: UAB is enrolling patients in the outpatient trials of ketamine and Glyx-13. Male and female patients ages 19-64 with a diagnosis of depression, who have failed two drug regimens for depression, are candidates for the trials. Total time involved in the studies, with treatment and follow-up, is about 13 weeks. Individuals interested in more information can contact the study coordinator at 205-975-2911 or hammond@uab.edu.

Related Stories

Ketamine improved bipolar depression within minutes

date May 30, 2012

Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide ...

Ketamine helps see how the brain works in clinical depression

date Jun 16, 2011

(Medical Xpress) -- In a new study published in Nature, Lisa Monteggia from the University of Texas Southwestern Medical Center looks at how the drug ketamine, typically used as an anesthetic or a popular recreational drug f ...

Ketamine reduces suicidality in depressed patients

date Sep 10, 2009

Drug treatment options for depression can take weeks for the beneficial effects to emerge, which is clearly inadequate for those at immediate risk of suicide. However, intravenous (IV) ketamine, a drug previously used as ...

'Special K' could relieve depression

date Jun 07, 2012

(Medical Xpress) -- Recreational drug and anaesthetic, ketamine, is being trialled in people with severe depression and is providing almost instant relief from symptoms, offering fresh hope of a quick new ...

Recommended for you

Homely men who misbehave can't win for losing

date 2 hours ago

Women tolerate an unattractive man up to a point, but beware if he misbehaves. Then they'll easily shun him. So says Jeremy Gibson and Jonathan Gore of the Eastern Kentucky University in the U.S., after finding ...

Challenging students benefit from limit setting

date 3 hours ago

The teacher's interaction style can either foster or slow down the development of math skills among children with challenging temperaments. This was shown in the results of the study "Parents, teachers and children's learning" ...

Are antidepressants more effective than usually assumed?

date 3 hours ago

Many have recently questioned the efficacy of the most common antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs). The conclusion that these drugs are ineffective is however partly ...

The analogy that builds human thought

date 3 hours ago

When Niels Bohr hypothesised his model of atom with the electrons orbiting the nucleus just like satellites orbit a planet, he was engaging in analogical reasoning. Bohr transferred to atoms the concept of ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.